- $1.07bn
- $1.02bn
- $73.24m
- 94
- 11
- 97
- 77
Annual balance sheet for Iradimed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 52 | 62.5 | 58 | 49.8 | 52.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.57 | 5.14 | 13.3 | 12.2 | 10.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 63.7 | 76.2 | 77.5 | 76 | 75.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.84 | 4.55 | 4.61 | 11.3 | 17 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 71.1 | 82.9 | 85.5 | 92.2 | 98.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.92 | 6.82 | 8.55 | 16.3 | 8.51 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.68 | 10.7 | 11.8 | 20.7 | 11.5 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 61.4 | 72.2 | 73.7 | 71.4 | 86.8 |
| Total Liabilities & Shareholders' Equity | 71.1 | 82.9 | 85.5 | 92.2 | 98.3 |
| Total Common Shares Outstanding |